Point-of-care genetic testing for personalisation of antiplatelet treatment
Rapid Gene: A prospective, randomised, proof-of-concept trial
- Rapid genetic testing after PCI can be effectively done at the bedside to identify CYP2C19*2 LOF allele carriers
- This prospective, randomized 200-patient study reported that tailored, genotype-guided treatment of CYP2C19*2 carriers can reduce high on-treatment platelet reactivity, which is commonly associated with increased risk for major adverse cardiovascular events
- This study is the first reported use of an FDA-cleared, rapid CYP2C19 genetic test (Spartan’s RX CYP2C19 System), and offers a novel solution to overcome limitations in pharmacogenomics
